Sparking Transformation in Healthcare
egnite is a company with a vision:
to identify and improve outcomes for every cardiovascular patient in the U.S.
Sparking Transformation in Healthcare
egnite is a company with a vision:
to identify and improve outcomes for every cardiovascular patient in the U.S.
Using Big Data to Solve Big Problems 
Advancing the Cardiovascular Health of Our Society
egnite is a digital health company leveraging artificial intelligence-driven algorithms to produce business intelligence for healthcare, elevating the role of data in critical decisions.
FOR HEALTH PROFESSIONALS
The CardioCare Platform
by artificial intelligence
FOR LIFE SCIENCES 
egnite Therapy Accelerator & Research
of real-world cardiovascular data
Podcasts
egnite COO, Jessica Neufeld, discusses the current state of A.I. adoption and challenges in healthcare, along with the role of technology in improving patient care on a recent episode of Microsoft’s Data and A.I. podcast Insights Tomorrow.
egnite Senior Medical Advisor, Rahul Sharma, was recently featured on MedAxiom’s HeartTalk podcast to discuss how technology can be used to identify and treat patients before it’s too late.
Learn more from egnite CEO, Joel Portice, on how egnite is elevating the role of A.I. and big data to guide critical decisions in healthcare on Mike Moore’s The Bleeding Edge of Digital Health podcast.
Presented or Published in
Recognition
Testimonials
Leading health systems and life sciences organizations partner with egnite to transform care delivery for cardiovascular patients.
Gagnon Cardiovascular Institute, Morristown Medical Center
Director of Structural Interventions, Stanford Health Care
Senior Medical Advisor, egnite
Resources
SGLT2i + GLP-1 RA: A Dynamic Duo in HFpEF?
Heart failure with a preserved ejection fraction (HFpEF) accounts for more than half of all heart failure cases and carries significant morbidity and mortality risk, especially after hospitalization1. Historically, management of the disease is largely focused on comorbidity management and lifestyle modifications, given that available therapies had not demonstrated sufficient impact on hospitalization burden or mortality. In recent years, however, the treatment paradigm for HFpEF has shifted, with a growing emphasis on SGLT2 inhibitors (SGLT2i). Originally developed to lower blood glucose levels in diabetic patients, several clinical trials have firmly established that SGLT2i is also beneficial for patients living with HFpEF2.
Two-Year Mortality Following Heart Failure Hospitalization in Patients with HFpEF Stratified by SGLT2i and GLP-1 RA Therapy: A Real-World Analysis
BACKGROUND Heart failure with a preserved ejection fraction (HFpEF) is characterized by frequent hospitalizations, and substantial mortality. While historically lacking effective therapies, newer treatments, including SGLT2 inhibitors (SGLT2i) and GLP-1 receptor agonists (GLP-1 RA), have shown potential benefits. However, the clinical course of HFpEF under these therapies remains incompletely characterized, warranting further investigation. OBJECTIVES To […]
What the EARLY TAVR Trial Data Could Mean for Already Busy Heart Teams
On the heels of the exciting EARLY TAVR data and egnite’s Acute Valve Syndrome in Aortic Stenosis study, both led by Dr. Philippe Genereux, we’ve been asked by several cardiovascular (CV) administrators what a potential change in the management of asymptomatic severe aortic stenosis (SAS) patients could mean for their already busy heart teams.